story of the week
Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet 2024 Apr 06;403(10434)1341-1350, D Lorusso, Y Xiang, K Hasegawa, G Scambia, M Leiva, P Ramos-Elias, A Acevedo, V Sukhin, N Cloven, AJ Pereira de Santana Gomes, F Contreras Mejía, A Reiss, A Ayhan, JY Lee, V Saevets, F Zagouri, L Gilbert, J Sehouli, E Tharavichitkul, K Lindemann, R Lazzari, CL Chang, R Lampé, H Zhu, A Oaknin, M Christiaens, S Polterauer, T Usami, K Li, K Yamada, S Toker, SM Keefe, S Pignata, LR DuskaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.